# Saturn V Capital Management LP

> Institutional holdings reported to the SEC as of Q2 2026 on Form 13F. CIK 1964437. Source: https://holderbook.com/funds/1964437-saturn-v-capital-management-lp/

- Reported value: $697.5M
- Positions: 23
- Weight of the ten largest: 75.6%
- Filed: 2026-08-14

A 13F reports long US equity positions only. Short positions, bonds, foreign listings, private holdings and cash are not visible, so this is not the manager's whole book.

## Holdings

| Security | Ticker | Value | Shares | Weight | Quarters held |
|---|---|---|---|---|---|
| AMYLYX PHARMACEUTICALS INC | [AMLX](https://holderbook.com/stocks/AMLX/) | $83.0M | 4,624,101 | 11.9% | 7 |
| ALUMIS INC | [ALMS](https://holderbook.com/stocks/ALMS/) | $82.0M | 2,915,443 | 11.8% | 3 |
| ABIVAX SA | [ABVX](https://holderbook.com/stocks/ABVX/) | $69.1M | 518,865 | 9.9% | 10 |
| VAXCYTE INC | [PCVX](https://holderbook.com/stocks/PCVX/) | $49.6M | 852,914 | 7.1% | 10 |
| IMMIX BIOPHARMA INC | [IMMX](https://holderbook.com/stocks/IMMX/) | $48.0M | 4,658,429 | 6.9% | 3 |
| PHARVARIS N V | [PHVS](https://holderbook.com/stocks/PHVS/) | $45.4M | 1,314,122 | 6.5% | 4 |
| JAZZ PHARMACEUTICALS PLC | [JAZZ](https://holderbook.com/stocks/JAZZ/) | $38.8M | 160,938 | 5.6% | 5 |
| CELCUITY INC | [CELC](https://holderbook.com/stocks/CELC/) | $38.7M | 370,318 | 5.6% | 9 |
| DISC MEDICINE INC | [IRON](https://holderbook.com/stocks/IRON/) | $38.4M | 524,730 | 5.5% | 11 |
| CANDEL THERAPEUTICS INC | [CADL](https://holderbook.com/stocks/CADL/) | $34.0M | 3,303,686 | 4.9% | 2 |
| X4 PHARMACEUTICALS INC | [XFOR](https://holderbook.com/stocks/XFOR/) | $32.6M | 6,973,343 | 4.7% | 3 |
| MONOPAR THERAPEUTICS INC | [MNPR](https://holderbook.com/stocks/MNPR/) | $28.9M | 311,976 | 4.1% | 4 |
| DYNE THERAPEUTICS INC | [DYN](https://holderbook.com/stocks/DYN/) | $23.5M | 1,057,493 | 3.4% | 5 |
| TREVI THERAPEUTICS INC | [TRVI](https://holderbook.com/stocks/TRVI/) | $19.6M | 1,052,043 | 2.8% | 1 |
| ZURA BIO LTD | [ZURA](https://holderbook.com/stocks/ZURA/) | $12.4M | 2,101,119 | 1.8% | 2 |
| SAGIMET BIOSCIENCES INC | [SGMT](https://holderbook.com/stocks/SGMT/) | $11.4M | 1,479,918 | 1.6% | 1 |
| OCULIS HOLDING AG | [OCS](https://holderbook.com/stocks/OCS/) | $9.5M | 684,880 | 1.4% | 3 |
| INHIBIKASE THERAPEUTICS INC | [IKT](https://holderbook.com/stocks/IKT/) | $7.9M | 3,869,056 | 1.1% | 3 |
| VIR BIOTECHNOLOGY INC | [VIR](https://holderbook.com/stocks/VIR/) | $7.9M | 770,643 | 1.1% | 1 |
| INVIVYD INC | [IVVD](https://holderbook.com/stocks/IVVD/) | $7.3M | 8,392,288 | 1.0% | 3 |
| ALTO NEUROSCIENCE INC | [ANRO](https://holderbook.com/stocks/ANRO/) | $4.8M | 182,829 | 0.7% | 2 |
| SATELLOS BIOSCIENCE INC | [MSLE](https://holderbook.com/stocks/MSLE/) | $2.7M | 350,000 | 0.4% | 2 |
| OVID THERAPEUTICS INC | [OVID](https://holderbook.com/stocks/OVID/) | $1.8M | 663,060 | 0.3% | 3 |

## What the disclosed book did

Not the fund's return. This is the change in value of the positions disclosed on Form 13F, had they been left untouched, against SPY over the same quarter ends.

| Quarter | Book | Market | Difference | Priced |
|---|---|---|---|---|
| Q2 2026 | +18.2% | +14.8% | +3.4% | 100% |
| Q1 2026 | +9.1% | -4.6% | +13.7% | 100% |
| Q4 2025 | +29.7% | +2.4% | +27.3% | 100% |
| Q3 2025 | +75.1% | +7.8% | +67.3% | 100% |
| Q2 2025 | +10.8% | +10.5% | +0.4% | 100% |
| Q1 2025 | -21.2% | -4.6% | -16.7% | 100% |
| Q4 2024 | -15.8% | +2.1% | -18.0% | 100% |
| Q3 2024 | +10.1% | +5.4% | +4.7% | 99% |

## Quarter by quarter

| Quarter | Value | Positions |
|---|---|---|
| Q2 2026 | $697.5M | 23 |
| Q1 2026 | $552.2M | 21 |
| Q4 2025 | $544.9M | 20 |
| Q3 2025 | $456.0M | 17 |
| Q2 2025 | $246.8M | 24 |
| Q1 2025 | $198.2M | 21 |
| Q4 2024 | $255.4M | 24 |
| Q3 2024 | $279.8M | 25 |
| Q2 2024 | $264.6M | 26 |
| Q1 2024 | $249.4M | 21 |
| Q4 2023 | $261.2M | 23 |
| Q3 2023 | $238.9M | 20 |